507 related articles for article (PubMed ID: 19253106)
21. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
Rigla M; Wägner AM; Borrell M; Mateo J; Foncuberta J; de Leiva A; Ordóñez-Llanos J; Pérez A
Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
[TBL] [Abstract][Full Text] [Related]
22. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
[TBL] [Abstract][Full Text] [Related]
23. Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M
Transplant Proc; 2006; 38(1):105-7. PubMed ID: 16504676
[TBL] [Abstract][Full Text] [Related]
24. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
25. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
26. The effect of the acute submaximal exercise on thrombin activatable fibrinolysis inhibitor levels in young sedentary males.
Kahraman S; Bediz CS; Pişkin O; Aksu I; Topçu A; Yüksel F; Demirkan F
Clin Appl Thromb Hemost; 2011 Aug; 17(4):414-20. PubMed ID: 21078613
[TBL] [Abstract][Full Text] [Related]
27. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
Ricart JM; Ramón LA; Vayá A; España F; Santaolaria ML; Todolí J; Castelló R; Fontcuberta J; Estellés A
Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
[TBL] [Abstract][Full Text] [Related]
28. Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index.
de Mendonça-Louzeiro MR; Annichino-Bizzacchi JM; Magna LA; Quaino SK; Benetti-Pinto CL
Fertil Steril; 2013 May; 99(6):1786-90. PubMed ID: 23415973
[TBL] [Abstract][Full Text] [Related]
29. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome.
Kebapcilar L; Taner CE; Kebapcilar AG; Sari I
Arch Gynecol Obstet; 2009 Aug; 280(2):187-93. PubMed ID: 19107500
[TBL] [Abstract][Full Text] [Related]
30. Balance of coagulation activity with fibrinolysis during use of oral contraceptives in women with insulin-dependent diabetes mellitus.
Petersen KR; Skouby SO; Jespersen J
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():105-11. PubMed ID: 8574252
[TBL] [Abstract][Full Text] [Related]
31. Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndrome.
Godtfredsen ACM; Sidelmann JJ; Gram JB; Andersen M; Glintborg D
Acta Obstet Gynecol Scand; 2020 Aug; 99(8):1078-1084. PubMed ID: 32048272
[TBL] [Abstract][Full Text] [Related]
32. Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation.
Mosnier LO; Elisen MG; Bouma BN; Meijers JC
Thromb Haemost; 2001 Oct; 86(4):1057-64. PubMed ID: 11686324
[TBL] [Abstract][Full Text] [Related]
33. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma.
Erem C; Kocak M; Nuhoglu I; Yılmaz M; Ucuncu O
Clin Endocrinol (Oxf); 2010 Oct; 73(4):502-7. PubMed ID: 20039901
[TBL] [Abstract][Full Text] [Related]
34. Coagulation and fibrinolytic parameters in normal pregnancy and in pregnancy complicated by intrauterine growth retardation.
Bellart J; Gilabert R; Fontcuberta J; Carreras E; Miralles RM; Cabero L
Am J Perinatol; 1998 Feb; 15(2):81-5. PubMed ID: 9514130
[TBL] [Abstract][Full Text] [Related]
35. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome.
Carmassi F; De Negri F; Fioriti R; De Giorgi A; Giannarelli C; Fruzzetti F; Pedrinelli R; Dell'Omo G; Bersi C
Thromb Res; 2005; 116(3):207-14. PubMed ID: 15935829
[TBL] [Abstract][Full Text] [Related]
36. Early markers of blood coagulation and fibrinolysis activation in Argentine hemorrhagic fever.
Heller MV; Marta RF; Sturk A; Maiztegui JI; Hack CE; Cate JW; Molinas FC
Thromb Haemost; 1995 Mar; 73(3):368-73. PubMed ID: 7667817
[TBL] [Abstract][Full Text] [Related]
37. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
[TBL] [Abstract][Full Text] [Related]
38. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
Saibeni S; Bottasso B; Spina L; Bajetta M; Danese S; Gasbarrini A; de Franchis R; Vecchi M
Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757
[TBL] [Abstract][Full Text] [Related]
39. Body fat composition and distribution in women with polycystic ovary syndrome.
Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
[TBL] [Abstract][Full Text] [Related]
40. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
